Latest conjunctivitis Stories
Viral keratoconjunctivitis, also known as pink eye, is a common, uncomfortable and highly contagious condition. There is no known effective treatment for this adenovirus infection that can force some individuals into isolation for up to two weeks
LOS ANGELES, April 9 /PRNewswire/ -- Newswise -- When a child develops red, watery eyes, it could be just allergies - or it may be the sign of a more serious eye condition, according to a leading pediatric ophthalmologist. According to Bibiana Jin Reiser, M.D., M.S., a pediatric ophthalmologist with The Vision Center at Childrens Hospital Los Angeles, "Red, itchy, watery eyes can be a temporary allergic reaction to pollen or other environmental irritants and should go away after a few days or...
MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies.
IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the U.S.
ATLANTA, Aug. 11 /PRNewswire/ -- MinuteClinic, the pioneer and largest provider of retail-based health care in the United States, is now offering a first-of-its kind rapid conjunctivitis (pink-eye) test at its 23 locations inside select CVS/pharmacy stores in the Atlanta area.
EMERYVILLE, Calif. and HUENENBERG, Switzerland, July 5 /PRNewswire-FirstCall/ -- Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc.
IRVINE, Calif., June 26 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S.
- Besivance Adds to Bausch & Lomb's Expanding Ocular Pharmaceuticals Portfolio and Offers New Therapeutic Option for a Wide Range of Ocular Bacterial Pathogens(1) - MADISON, N.J., May 29 /PRNewswire/ -- Bausch & Lomb, a world leader in eye health, today announced that the U.S.
PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better safety profile (no increase in intra-ocular pressure) than PredForte(TM), a prescription drug with a 10 fold higher dose of prednisolone acetate, in patients treated for the signs and symptoms (itching...
- Emitting flashes of light; glittering.